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calcium mishandling in absence of 
primary mitochondrial dysfunction 
drives cellular pathology in Wolfram 
Syndrome
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Wolfram syndrome (WS) is a recessive multisystem disorder defined by the association of diabetes 
mellitus and optic atrophy, reminiscent of mitochondrial diseases. The role played by mitochondria 
remains elusive, with contradictory results on the occurrence of mitochondrial dysfunction. We 
evaluated 13 recessive WS patients by deep clinical phenotyping, including optical coherence 
tomography (OCT), serum lactic acid at rest and after standardized exercise, brain Magnetic Resonance 
Imaging, and brain and muscle Magnetic Resonance Spectroscopy (MRS). Finally, we investigated 
mitochondrial bioenergetics, network morphology, and calcium handling in patient-derived fibroblasts. 
Our results do not support a primary mitochondrial dysfunction in WS patients, as suggested by MRS 
studies, OCT pattern of retinal nerve fiber layer loss, and, in fibroblasts, by mitochondrial bioenergetics 
and network morphology results. However, we clearly found calcium mishandling between endoplasmic 
reticulum (ER) and mitochondria, which, under specific metabolic conditions of increased energy 
requirements and in selected tissue or cell types, may turn into a secondary mitochondrial dysfunction. 
Critically, we showed that Wolframin (WFS1) protein is enriched at mitochondrial-associated ER 
membranes and that in patient-derived fibroblasts WFS1 protein is completely absent. These findings 
support a loss-of-function pathogenic mechanism for missense mutations in WFS1, ultimately leading 
to defective calcium influx within mitochondria.
Wolfram Syndrome (WS) is a rare genetic disorder also known as DIDMOAD, i.e. Diabetes Insipidus (DI), 
Diabetes Mellitus (DM), Optic Atrophy (OA) and Deafness1. Additional neurological features include brainstem 
atrophy, cerebellar ataxia, peripheral neuropathy, cognitive deterioration and epilepsy2. The onset of OA and DM, 
the minimal diagnostic criteria for WS, is typically within the second decade.
The large majority of WS patients carry recessive mutations in the WFS1 gene encoding for the Wolframin 
(WFS1) protein3. WFS1 is associated with the endoplasmic reticulum (ER)4 and cellular and animal model stud-
ies involved Wolframin in the ER stress response, regulation of calcium homeostasis and Na/K ATPase function5. 
Due to the clinical features resembling a mitochondrial disorder6 and reports of mitochondrial DNA (mtDNA) 
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abnormalities in WS7,8, a possible mitochondrial dysfunction has been debated with a long-standing contro-
versy9–12. In 1998, the identification of Wolfram Syndrome 1 (WFS1) gene mutations apparently resolved this 
issue3. However, recent reports resumed the debate documenting in Wfs1−/− mice disturbed mitochondrial 
network dynamics and activation of mitophagy13. Noticeably, recessive mutations in CDGSH Iron Sulfur Domain 
2 (CISD2) gene, encoding a protein localized in the mitochondria-associated ER membranes (MAMs), are causa-
tive for Wolfram syndrome type 214–19. As shown for Wfs1, also Cisd2 knock out mouse model and mouse embry-
onic fibroblast (MEF) studies documented mitochondrial dysfunction as evidenced by ultrastructural alterations 
of mitochondria, increased oxygen consumption and ADP/ATP ratio, and overload of mitochondrial calcium 
(Ca2+)20,21. Moreover, in patient-derived fibroblasts carrying a CISD2 mutation it has been reported enhanced 
Ca2+ efflux from mitochondria to ER and a mitochondrial bioenergetics defect17.
WS is typically characterized by severe optic atrophy with variable degrees of visual loss and visual field 
defects22. OCT studies documented in some case series a preferential involvement of the inferior sector of the 
optic nerve22, but one post-mortem study reported a prominent loss of retinal ganglion cell (RGC) axons in the 
temporal sector, implicating loss of the papillomacular bundle (PMB), the hallmark of mitochondrial optic neu-
ropathies such as Leber’s Hereditary Optic Neuropathy (LHON) and Dominant Optic Atrophy (DOA)23. Similar 
to DOA, WFS1 heterozygous mutations have been recently associated with dominant segregation of optic atrophy 
and deafness24.
We thoroughly investigated a cohort of 13 recessive WS adult cases by extensive neuro-ophthalmological and 
clinical evaluations. We revisited the issue of mitochondrial dysfunction by assessing venous lactic acid after 
standardized exercise, evaluating brain and skeletal muscle energy metabolism in vivo by proton and phosphorus 
MR spectroscopy (1H-MRS, 31P-MRS), and studying mitochondrial bioenergetics, network morphology and cal-
cium handling in patient-derived fibroblasts.
Results
Clinical and genetic findings in WS patients. Mean age for WS patients at our observation was 
32.9 ± 13.2 years (n = 13). Average age at onset of visual loss was 10 ± 4 years. Of the 13 subjects, 11 had diabetes 
mellitus with a mean age at onset of 15.5 ± 12.7 years (7/11 treated with insulin); 2 patients had diabetes insip-
idus and 6 had hearing loss. Urinary dysfunction was present in 7 subjects and psychiatric symptoms in 6. Five 
patients had a positive family history for WS. Two patients had consanguineous parents (first degree cousins).
The main clinical findings are summarized in Table 1.
Genetic analysis for mutations in WSF1 gene revealed compound heterozygous mutations in 8 subjects (61%), 
the remaining 5 carried homozygous mutations (38%) (Table 1).
Neuro-ophthalmological findings are summarized in Table 2.
Mean visual acuity was 0.20 ± 0.18 with impaired color vision in all cases, and abnormal pupillary response in 
11/13 (84%) patients. Fundus oculi was abnormal in all patients demonstrating diffuse optic nerve pallor in 10/13 
(77%) (more temporal in 5/10) and temporal pallor only in 3/13 (23%). Visual fields demonstrated a generalized defect 
in 11/13 (84%) and central scotoma in 2/13 (15%). OCT demonstrated diffuse and severe retinal nerve fiber thin-
ning in all cases examined. Average retinal nerve fibre layer (RNFL) thickness was 46.6 ± 6.1 micrometers (Fig. 1A). 
Quadrant RNFL thinning was consistent with fundus examination with the temporal sectors showing the lowest thick-
ness (32.3 ± 7.6), followed by nasal (43 ± 8.3), inferior (47.08 ± 7.06) and superior quadrants (62.7 ± 14.6) (Fig. 1B). 
Furthermore, we compared RNFL thickness data of WS patients to a group of 70 healthy age and sex-matched con-
trols and 16 DOA patients carrying Optic Atrophy 1 (OPA1) mutations (controls 32.1 ± 10.8, DOA 31.43 ± 14.1, WS 
31.5 ± 12.7 years of age) (Fig. 1A,B). The average and quadrants RNFL thickness results and comparisons between 
groups are shown in Fig. 1A,B. Statistical analysis with one-way ANOVA demonstrated a significant average RNFL 
thinning in both DOA and WS patients compared to controls (p < 0.001) (Fig. 1A). The average RNFL thickness was 
lower in WS compared to DOA (p < 0.001) (Fig. 1A), at difference of visual acuity (VA), which was not significantly 
different between groups (p = 0.9) (Table 2). Considering separately the four optic disc quadrants, one-way ANOVA 
with Bonferroni correction demonstrated a significant difference between groups for all quadrants, except for temporal 
and nasal quadrants, which resulted not significantly different in WS compared to DOA. The thickness of the four optic 
disc quadrants was significantly thinner in both WS and DOA compared to controls (p < 0. 001) (Fig. 1B).
The results on segmentation analysis (ganglion cell layer thickness) for the 9 sectors included are shown in 
Fig. 1C. One-way ANOVA with Bonferroni correction showed that the ganglion cell layer (GCL) thickness was 
significantly reduced in both WS and DOA compared to controls for all nine sectors (p < 0.001), whereas the 
difference between WS and DOA was not statistically significant for all sectors.
Lactic acid evaluation. Basal lactic acid values were normal in all patients assessed (12/13). Lactic acid 
after exercise was abnormal in 8/12 (66%) patients and in 4/8 (50%) remained abnormally elevated also after the 
recovery time (Table 1 and Fig. 1D).
Muscle biopsy. Muscle biopsy was performed in 3 patients (n. 4, n. 10, and n. 12 in Table 1). Muscle biopsy 
from patient 10 showed not specific alterations, such as mild variability of fiber size, some central nuclei, a few 
scattered cytochrome c oxidase (COX) negative fibers and an irregular distribution of oxidative activity with 
some fibers showing increased subsarcolemmal succinate dehydrogenase (SDH) staining; in one single fiber mul-
tiple cytoplasmic bodies were observed with the Gomori trichrome staining (Fig. 1E). This patient presented the 
most severe phenotype of the WS cases investigated (see Table 1). Muscle biopsy from patient n. 4 showed not 
specific changes with scattered atrophic fibers and rare central nuclei; cytoplasmic or subsarcolemmal rimmed 
vacuoles were observed in some muscle fibers; the staining for oxidative activity showed only a mild increase of 
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subsarcolemmal SDH staining in a few fibers, whereas COX negative fibers were absent (Fig. S1). Muscle biopsy 
from patient n.12 was normal (Fig. S1).
Brain magnetic resonance imaging and magnetic resonance spectrometry findings. Conventional 
brain Magnetic Resonance Imaging (MRI) findings are reported in Table 3. In all patients, brain MRI findings 
demonstrated atrophy of brainstem, with a T1 hypointensity in the ventral pons and thinning of bilateral ante-
rior optic pathway. Increased signal intensity in the bilateral peritrigonal areas/optic tracts was observed in 5/10 
patients in T2 weighted images. In all patients, the neurohypophyseal “bright signal” on T1-weigheted images 
was present.
Voxel-based morphometry (VBM) showed cortical grey matter volume loss in the calcarine (p < 0.05) and 
cerebellar cortices (p < 0.001), specifically in the bilateral I-IV, V, VI, VIIb, and left VIIIa; bilateral crus I, II; and 
vermis VI, VIIIa, IX (Fig. S2 and Table S1). FreeSurfer analysis showed lower total intracranial volume (TIV) 
(p = 0.018) and lower volume of ventral diencephalon, brainstem and cerebellar white matter in WS patients 
(p < 0.001) (Fig. 2 and Table S2).
Tract-Based Spatial Statistics (TBSS) highlighted lower fractional anisotropy (FA) (driven by radial diffusivity 
increase) for patients mostly within optic radiations and optic tracts, posterior limbs of internal capsules, cere-
bellar peduncles (inferior, middle and superior) and to less extent corpus callosum (p < 0.05, corrected) (Fig. S2 
and Table S1).
WS patients had lower cerebellar hemisphere N-acetyl-aspartate/Creatine (NAA/Cr) (p = 0.003) and lower 
N-acetyl-aspartate/myoinositol (NAA/mI) (p < 0.001) and higher mI/Cr (p = 0.012) in comparison to controls. 
Lower NAA/Cr (p = 0.004) and NAA/mI (p = 0.005) were found in the ventral pons, while no differences were 
found in parieto-occipital white matter (POWM) (Table S3).
1H-MRS failed to demonstrate, likewise in healthy controls, pathological accumulation of lactate in lateral 
ventricles in all WS patients. 31P-MRS muscle metrics showed no differences between patients and controls at rest, 
during exercise and the post-exercise recovery (Table 4). In particular, WS patients showed normal post-exercise 
indices of muscle oxidative metabolism such as time constant (TC) of phosphocreatine (PCr) resynthesis and 
maximum rate of mitochondrial ATP synthesis.
ID Mutation Effect Age DM onset
DM 
Therapy
HbA1c 
(mmol/ 
mol)
Diabetes 
insipidus
Hearing 
loss
Psychiatric 
symptoms
Urinary 
symptoms Other symptoms
LA basal, 
a.e. and a.r. 
(mg/dl) Muscle biopsy
1 c.1381 A > Cc.1675G > A
p.T461P
p.A559T 28 3 insulin 47 − + + + none
8,5-49-33 
(2015)
5.5-55.5-
32.5(2017)
NA
2 c.409_426dup16 c.2104 G > A
p.V142fsX251
p.G702S 25 10 insulin 71 − − − −
migraine early 
puberty 11-17-19 NA
3 c.2002C > Tc.2126 T > G
p.Q668X
p.V709G 42 13 insulin 56 − + − +
central apnea 
dysphagia 15-21-15 NA
4 c.977 C > T(homo) p.A326V 56 15 insulin 60 − + + −
fallot tetralogy 
bicameral PM
13.4-37.8-
26.2 normal
5 c.605 A > G(homo) p.E202G 22 10 diet 42 − − − + none 8-35-17 NA
6 c.1369 A > G c.2104 G > A
p.R457G
p.G702S 24 19 insulin <42 − − − + none 10,5-38-26 NA
7 c.1928T > Gc.2194 C > T
p.L543R
p.R732C 47 38 − − + − hypertension 15-32-22 NA
8 c.1928T > Gc.2194 C > T
p.L543R
p.R732C 41 29 oral NA − + − − glaucoma NA NA
9 c.2206 G > A (homo) p.G736S 37 11 oral NA + − + + none 13-53-43 NA
10 c.1552 A > Cc.2084 G > T
p.T471P
p.G695V 50 47 oral NA + + + +
dementia 
dysphagia ataxia 5.5-32.4-19
Mild signs of 
mitochondrial 
myopathy
11 c.2104 G > A c.2453_66dup14
p.G702S
p.F724SfsX766 18 12 insulin NA − − NA NA none
9.3-8.4-17.7-
11.9 NA
12 c. 1553 T > A (homo) p.M518K 16 36 − − − − none
9-54-32 
(2014)
7.1-6.6-31.5-
14.7 (2017)
normal
13 c.387 G > A(homo) p.W189X 22 2 insulin 67 − + + + hypothiroidism
8.1-8.9-9.2-
6.5 NA
Table 1. Clinical findings in WS cohort. The table shows for each patient genetic and clinical findings. Available 
muscle biopsies and laboratory results (HbA1c and LA levels after excercise) are also shown. a.e. after exercise; 
a.r. after recovery. In bold and underlined abnormal LA values (normal values 5–22 mg/dL). Hom: homozygous, 
DM: diabetes mellitus, NA not available, LA: lactic acid.
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None of the MRI metrics showed significant correlation with the age of patients, with exception of the NAA/
Cr ratio in the cerebellar hemisphere, which showed a strong correlation with age in WS patients (rho = −0.817, 
p = 0.007), but not in healthy controls (rho = 0.006; p = 0.987).
Fibroblast cell studies. Fibroblasts derived from two WS patients were studied to evaluate WFS1 protein 
expression, mitochondrial bioenergetics, mitochondrial network morphology and intracellular Ca2+ dynamics.
WFS1 protein expression was evaluated by Western blot in control and WS fibroblasts. Although both patients 
carried missense mutations in WFS1, we observed a dramatic reduction of WFS1 expression in mutant fibroblasts 
compared to controls (p = 0.0013) (Fig. 3A), indicating the presence of a loss-of-function mechanism. Oxygen 
consumption, an indicator of mitochondrial respiratory capacity, resulted comparable in WS and control fibro-
blasts, both in basal condition and after the addition of oligomycin (ATP-linked respiration) and carbonyl cyanide 
4-(trifluoromethoxy) phenylhydrazone (FCCP) (maximal respiration) (Fig. 3B,C). Concordantly, mitochondrial 
membrane potential was not affected in WS fibroblasts (Fig. 3D). Total ATP was increased, although not reaching 
a statistical significance, in WS fibroblasts compared to controls, in standard conditions (glucose medium) and 
when cells were forced to use mitochondria to produce ATP (galactose medium) (Fig. 3E). Moreover, as shown in 
the energetic map (Fig. 3F), WS and controls cells had similar oxygen consumption rate (OCR) but extracellular 
acidification rate (ECAR), an indicator of glycolysis, was increased in WS cells compared to controls (p = 0.0168), 
suggesting a higher contribute of glycolysis rather than mitochondrial respiration to the cellular ATP production. 
Mitochondrial network morphology was not compromised in patients’ fibroblasts grown in glucose-medium, 
since the percentage of cells characterized by filamentous, intermediate and fragmented mitochondria was com-
parable to that of control fibroblasts. After 48 hours of incubation in the galactose-medium, the percentage of 
cells with fragmented mitochondria was again similar in WS and control fibroblasts, indicating the absence of a 
mitochondrial network morphology defect, congruent with a normal bioenergetic function (Fig. 3G,H).
Different reports indicate that mitochondrial metabolism and ATP production are both mechanisms finely 
tuned by Ca2+ dynamics, in particular by a proper ER-mitochondrial Ca2+ transfer25. When the ER-Ca2+ 
release is evoked, Ca2+ can be released directly into cytosol or taken up by mitochondria. Increases in this 
intra-mitochondrial Ca2+ levels, in turn, stimulates ATP production throughout activation of Ca2+-sensitive 
dehydrogenases belonging to the Krebs cycle. Hence, we decided to investigate Ca2+ handling, implicating the 
ER, mitochondrial and cytosol compartments, by measuring agonist dependent Ca2+ transients in healthy con-
trol and Wolfram fibroblasts. Cells were transfected with ER targeted cameleon (D1ER), a fluorescent probe 
that monitors ER-Ca2+ concentration variations, and then stimulated with the agonist bradykinin (BK), which 
induces ER Ca2+ release through the IP3Rs. We found that WS fibroblasts released lower amounts of Ca2+ from 
the ER, than control samples (Fig. 4A,B). This result suggested that Wolfram cells were characterized by a reduced 
flux of Ca2+ from the ER. As consequence, we found lower Ca2+ accumulations in mitochondria (Fig. 4C,D) and 
ID Age
Visual 
loss 
onset
VA 
(OD VA OS Pupils
Ishihara 
Test
FOO Optic 
disc pallor
FOO 
pigmentary 
changes FOO others VF Defect
VF MD 
(dB) OD
VF MD 
(dB) 
OS
VF 
Fovea 
OD
VF 
Fovea 
OS
1 28 10 0,013 0,01 sluggish (L > R) 0/12 diffuse mild peripheral tilted disk diffuse −33,76 −33,71 NA NA
2 25 17 0,32 0,4 sluggish (R > L) 0/12
temporal 
(R > L) none Retinal drusen diffuse −3,37 −2.76 33 31
3 42 10 0,08 0,025 miotic;no response 0/12 diffuse
macular 
dystrophy OD small disc diffuse −19,96 −22,61 24 15
4 56 6 0,02 0,01 sluggish (L > R) 0/12 diffuse (>T) none
diabetic 
retinopathy; 
macular drusen
diffuse −31,04 −30,59 NA NA
5 22 10 0,16 0,25 sluggish NA temporal mild perifoveal salt-pepper none central scotoma −6,17 −4.36 23 27
6 24 6 0,4 0,63 sluggish (R > L) 0/12 diffuse (>T) none none diffuse −4.37 −5,94 31 35
7 47 6 0,5 0,4 sluggish (R > L) 0/12 diffuse (>T) none
small disc, 
temporal 
excavation
diffuse −5,51 −6,74 33 31
8 41 17 0,125 0,16 sluggish (L > R) 0/12 diffuse none
peripheral 
retinal drusen diffuse −5.89 −2.27 27 22
9 37 11 0,063 0,063 no response (L > R) 0/12
temporal 
(R > L) none none diffuse −18.80 −24.09 26 20
10 50 6 0,02 0,06 sluggish (R > L) NA diffuse (>T) NA none central scotoma NA NA NA NA
11 18 12 0,32 0,25 normal NA diffuse none none diffuse −6.25 −9.07 NA NA
12 16 13 0,4 0,32 normal 0/12 diffuse (>T) none
perifoveal 
drusen, retinal 
cysts (L > R)
diffuse −6.15 −5.60 33 32
13 22 6 0.16 0.013 no response 0/12 diffuse none none diffuse −30.20 −34.08 19 16
Table 2. Neuro-ophthalmological results in WS cohort. VA: visual acuity; OD: right eye; OS: left eye; R: right; 
L: left; T: temporal; BOO: biometry, FOO: fundus; ON: optic nerve; VF: visual fields; MD: mean deviation, NA: 
not available.
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cytosol (Fig. 4E,F) in WSF fibroblasts as compared to controls after BK stimulation, without finding any variation 
in the resting mitochondrial Ca2+ levels (Fig. 4G). The correct Ca2+ transmission between ER and mitochondria 
is finely tuned by the contact sites between the organelles, known as MAMs26. Different proteins have been found 
to localize in these fractions and determine positive or negative modulation of Ca2+ transmission between ER 
and mitochondria27. Having found an important deregulation in mitochondrial Ca2+ accumulation in Wolfram 
fibroblasts, we asked whether Wolfram would be localized at MAMs site to regulate Ca2+ homeostasis. Subcellular 
fractionation confirmed this hypothesis and revealed that WFS1 was present in considerable amounts in the 
MAMs compartment (Fig. 4H).
Figure 1. OCT, lactic acid and skeletal muscle results. (A,B) Panel A and Panel B show, respectively, average 
and single quadrant RNFL thickness in the tree groups (Controls, DOA, WS). ***p < 0. 001 one-way ANOVA 
test. (C) Panel C shows sectorial GCL thickness.RNFL: retinal nerve fiber layer; AVG: average; T: temporal; 
S: superior; N: nasal; I: inferior; int: internal; ext: external; GCL: ganglion cells layer; DOA: dominant optic 
atrophy; WS: Wolfram syndrome. ***p < 0. 001 one-way ANOVA test. (D) Lactic acid measured in blood at 
baseline, after exercise and after recovery time in 12 WS patients. Normal values: 5–22 mg/dL. (E) COX/SDH, 
HE and Gomori modified trichrome staining of the muscle biopsy from patient n. 10. Two COX negative fibers 
(blue fibers highlighted in the insets), two fibers with central nuclei and one fiber with cytoplasmic bodies are 
pointed by arrows. Bars: 100 µm.
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Discussion
Our study, by using multiple in vivo and in vitro approaches, demonstrates the absence of a primary mitochon-
drial dysfunction in WS patients. However, in specific tissue or cell types characterized by high energy require-
ments (i.e neuronal cells), a secondary metabolic dysfunction may occur likely mediated by calcium mishandling 
between ER and mitochondria. In support of this interpretation, we documented that WFS1 is enriched at 
MAMs, and the virtual absence of WFS1 protein in WS patients, as also reported by others28, most probably leads 
to the documented defective calcium efflux from ER.
WS is a neurodegenerative disorder typically characterized by the occurrence of optic atrophy and diabetes in 
childhood, frequently with additional symptoms, such as diabetes insipidus, deafness, and psychiatric disorders29. 
Case
Sovratentorial Brain Infratentorial Brain
Atrophy Signal alterations Neuro-
Hypophyseal 
“bright 
signal”
Atrophy Signal alterations
Cerebral
Anterior 
Optic 
Pathway
White Matter (T2 
hyperintensity & T1 
hypointensity) Mesencephalon Pons
Medulla 
allungata Cerebellum Pons
Case 1 
(CA)
parietal cortex
III ventricle enlargement severe peritrigonal/optic radiations present moderate severe moderate moderate T1 hypointensity
Case 2 
(BM) / moderate optic radiations present / mild / / T1 hypointensity
Case 3 
(AH) / mild / present / mild / / T1 hypointensity
Case 4 
(DEF) / mild / present / moderate / / T1 hypointensity
Case 5 
(VS)
parieto-occipital cortex
III ventricle enlargement moderate peritrigonal/optic radiations present mild severe moderate moderate T1 hypointensity
Case 6 
(MT) / mild / present / mild / / T1 hypointensity
Case 7 
(BL)
mild III ventricle 
enlargement moderate peritrigonal/subcortical present / moderate / / T1 hypointensity
Case 8 
(ME) / severe peritrigonal/optic radiations present / mild / mild T1 hypointensity
Case 9 
(BS)
mild III ventricle 
enlargement severe / present / moderate mild / T1 hypointensity
Case 
10 
(RS)
parieto-occipital cortex moderate / present / moderate mild mild T1 hypointensity
Table 3. Conventional Brain MRI findings in Wolfram syndrome patients. /= absent.
Figure 2. Regional Subcortical Volumes: WS patients vs healthy controls. (A) The brain regions which resulted 
atrophic in WS patients compared to healthy controls are highlighted on sagittal and coronal views from the T1 
image of a representative WS patient (dorsal and ventral pons, midbrain, cerebellar white matter and diencefalic 
region, p < 0.001, light red, and cerebellar cortices and bilateral thalami with a lesser degree of atrophy, 
p < 0.05, dark red). Images are shown in radiological convention (left is right). (B) Significant results (*p < 0.05, 
**p < 0.01, ***p < 0.001) of the comparisons are reported in the bar plot. For a complete overview of p values, 
averages and multiple comparisons corrections see Table S2. DC: Diencephalon; WS: Wolfram syndrome.
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Given the close similarity of WS with mitochondrial disorders, we thoroughly investigated the occurrence of 
mitochondrial abnormalities in WS patients. Lactic acid evaluation after standardized exercise showed abnor-
mally increased lactic acid only after exercise in most patients. However, a confounding factor impinging on 
the evaluation of this parameter is the concomitant presence of diabetes in these patients, which may result in 
abnormal increase of lactic acid, as previously reported30, indicative of enhanced non-oxidative glycolysis leading 
to lactate accumulation31.
Considering the ophthalmological phenotype of our WS patients, we found a pattern of diffuse optic atrophy, 
not strictly selective for the temporal fibers of the papillomacular bundle, which is instead typical for DOA, a 
disease with a primary mitochondrial dysfunction32. Overall, WS patients showed a more severe RNFL thinning 
at OCT, significant in comparison to DOA patients for all sectors except for the nasal and temporal quadrants. 
Interestingly, the significant loss of retinal nerve fibers in WS does not translate into a significant reduction of 
visual acuity compared to DOA, pointing to a more generalized loss of fibers in the optic nerve, not specific for 
the papillo-macular bundle, at difference with mitochondrial optic neuropathies33.
Visual field (VF) demonstrated the presence of a central scotoma only in 2 WS cases, whereas for other WS 
patients visual field defects were heterogenous, again not suggesting a classical mitochondrial pattern34. The 
neuro-ophthalmological phenotype has been poorly defined in WS until recently35–37. Grenier and colleagues22 
evaluated OCT findings in 15 WS cases. Eleven patients carried autosomal recessive (ar)-WS mutations (8 with 
diabetes and 3 without diabetes) and four patients carried autosomal dominant (ad)-WS mutations in association 
with hearing loss. The authors reported with spectral domain OCT a more profound RNFL thinning in syndro-
mic ar-WS than in WS cases without diabetes, especially in the inferior sector of the optic nerve. Time-domain 
OCT demonstrated a more severe RNFL thinning in the ar-WS group in both the superior and inferior quad-
rants compared with ad-WS cases22. Another study investigated OCT findings in 12 genetically-confirmed 
WS children. WS patients showed a greater RNFL thinning especially in the superior and inferior sectors and 
in the brain MRI visual pathway measurements compared with individuals with type 1 diabetes and controls. 
Interestingly, the thickness of the intraorbital parts of the optic nerves evaluated by brain MRI correlated with 
the superior RNFL thickness of the optic nerve37. Moreover, OCT demonstrated optic nerve thinning in a group 
of WS patients followed over a period of about 2 years36. Further studies are needed to firmly consolidate the 
neuro-ophthalmological features of WS and their natural history progression.
Brain MRI findings have been previously reported in WS patients38–40 and atrophy of the cerebellar corti-
ces and brainstem, specifically in the pons, are well-documented features. Interestingly, at visual inspection, we 
observed a pathological dilatation of the inferior aspect of the third ventricle in four patients, two of them with 
diabetes insipidus, confirmed by a FreeSurfer group analysis detection of high - significant volume reduction 
in the ventral diencephalic region. These results are consistent with the postmortem study of one WS patient 
showing a specific neuronal loss in paraventricular and supraoptic nuclei in the hypothalamus41. We expanded 
the findings of the cerebellar atrophy reporting a significant age-related NAA/Cr loss in the cerebellar hemi-
sphere, revealed with a single voxel 1H-MRS, suggesting a degenerative neurometabolic process at this level, 
which evolves with age. The atrophy of the ventral pons was associated in all patients with T1 hypointensity 
present in pons in 3D fast spoiled gradient echo (FSPGR) images. This patchy MRI signal abnormality in the 
ventral pons is consistent with a previous neuropathological study of a patient showing a patchy pattern of loss 
in the pontine base, in which areas of gliosis alternated to areas in which neurons are spared, with no preferential 
involvement of a specific area41. In the sovratentorial brain, we confirmed diffuse white matter changes without 
significant NAA/Cr loss or correlations with the age of patients, suggesting a primary neuropathological feature 
of Wolfram Syndrome, as previously reported40. MRS studies clearly failed to demonstrate the presence of brain 
and skeletal muscle oxidative metabolism in WS patients at different stages of disease, in contrast with previous 
findings in patients with mitochondrial optic neuropathies such as LHON and DOA (OPA1 mutations)42,43. The 
failure of documenting a primary defect of skeletal muscle oxidative metabolism reinforces the interpretation that 
Variable
WS (n = 8, 
age = 31 ± 13 y, 2 M)
Controls (n = 8, 
age = 32 ± 11 y, 4 M)
Mann-
Whitney Test
mean (SD) mean (SD) p value
Rest pH 7.02 0.02 7.03 0.002 0.20
PCr/Pi 8.05 1.31 7.56 1.24 0.51
WS
(n = 6, age 33 ± 14 y, 
1 M)
Controls
(n = 6, 
age = 32 ± 11 y, 2 M)
Exercise Duration (min) 4.34 2.92 4.82 2.40 1
End-exercise
pH 6.91 0.11 6.85 0.11 0.31
[PCr] % 40.1 11.7 41.5 11.0 0.70
Post-exercise recovery
TC PCr (sec) 39.44 7.99 35.33 9.16 0.59
Vmax (mM/min) 54.71 12.15 52.56 12.54 0.82
Table 4. Skeletal muscle 31P MR Spectroscopy results. Skeletal muscle 31P MR Spectroscopy results at rest, 
during aerobic exercise and in the post-exercise recovery in WS patients (6/8 performed muscle exercise) 
and matched healthy controls (n = 8). Data is reported as mean ± SD years; pH= cytosolic pH; PCr, 
phosphocreatine; Pi, inorganic phosphate; [PCr] %= PCr concentration at the end of exercise expressed as 
percentage of the concentration at rest; TC PCr: time constant of PCr resynthesis; Vmax: maximum rate of 
mitochondrial ATP synthesis.
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Figure 3. Mitochondrial capacity in Wolfram fibroblasts. (A) WFS1 quantification by Western blot. A 
representative image grouping different parts of the same blot (original images in Supplementary information 
file) and densitometric analysis are shown. Error bars, s.d. of three biological replicates. **p < 0.01 upaired 
t-test. (B) Oxygen consumption rate (OCR) traces of control and Wolfram fibroblasts, expressed as pmol O2/
min, in basal conditions and after the injection of oligomycin (O), carbonyl cyanide 4-(trifluoromethoxy)
phenylhydrazone (FCCP; F), rotenone (R) and antimycin A (AA). OCR values are normalized on protein 
content (SRB). Error bars, s.d. of two independent experiments for each cell line. (C) Basal, ATP-linked and 
maximal respiration were calculated from OCR traces and are reported in the graph as means ± s.d. Differences 
are not significant based on the two-way ANOVA test. (D) Mitochondrial membrane potential expressed as JC-1 
fluorescences ratio (590 nm/529 nm). Error bars, s.d. of four independent experiments for each cell line. (E) 
Cellular ATP content measured in standard conditions (glucose-medium) and after 48 hours of incubation in 
a glucose-free medium supplemented with 5 mM galactose. Error bars, s.d. of 2 independent experiments for 
each cell line. Differences are not significant based on the two-way ANOVA test. (F) Energetic map reporting 
basal OCR and ECAR values normalized on protein content (SRB). Error bars, s.d. of two independent 
experiments for each cell line. *p < 0.05 unpaired t-test. (G) Classification of cells based on the mitochondrial 
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increase of lactic acid after standardized effort is ascribed to the concurrent diabetes. In addition, the analysis of 
three muscle biopsies from our patients were not informative for a clear-cut primary mitochondrial dysfunction, 
in line with a previous report44.
Similarly to MRS, fibroblast studies did not support the presence of defective mitochondrial bioenergetics and 
network morphology, differently from previous reports13. Concordantly with our results, a recent study failed 
to evidence any defect in mitochondrial morphology or mitochondrial membrane potential in fibroblasts from 
WS patients carrying loss-of-function mutations in WFS128. On the other hand, in this study WS fibroblasts 
showed impaired OCR and activity of complexes I and IV, possibly related to a reduced expression of the neuronal 
calcium sensor 1 (NCS1), an interactor of WFS128. The discrepancy between our and these previous findings 
can be referred to the different models used, i.e. neuronal cells from knockout mice13, or to the inter-individual 
phenotypic expression in WS patients and consequently in fibroblast cell lines, as already reported for OPA1 
mutations45.
Interestingly, the tendency of increased cellular ATP content and the significantly higher ECAR, support the 
hypothesis of increased non-oxidative glycolysis, a possible effect of dysregulated glucose metabolism due to 
diabetes31.
Moreover, after stimulation with bradykinin, we observed an altered mitochondrial Ca2+ uptake driven by 
a reduced Ca2+ release from ER. Remarkably, we did not find variations in Ca2+ basal amounts, suggesting that 
the alteration in [Ca2+]m dynamics were not due to a general perturbation of the mitochondrial compartment. 
Supportive to this, changes were only found when we analyzed the driving force necessary for the passive Ca2+ 
entry into mitochondria. In addition, the possibility that decreases in [Ca2+]m uptake of patient fibroblasts were 
due to decreased ER calcium release was further confirmed by observing parallel reductions in cytosolic Ca2+ in 
response to IP3-evoked Ca2+ release.
An appropriated ER-mitochondrial Ca2+ transfer, followed by proper mitochondrial Ca2+ accumulation, 
is critical for numerous physiological processes and modulates the activity of several mitochondrial enzymes 
belonging to the Krebs cycle, because several dehydrogenases of the tricarboxylic acid cycle require Ca2+ to 
preserve the functioning of mitochondrial electron chain members. Among them, pyruvate dehydrogenase 
phosphatase 1 (PDP1) regulates the activity of pyruvate dehydrogenase, thus determining the metabolic fate of 
pyruvate46. Therefore, low levels of mitochondrial calcium uptake might also result in decreased activity of pyru-
vate dehydrogenase, leading to increased pyruvate conversion into lactate (non-oxidative glycolysis). WFS1 has 
been previously related to intracellular Ca2+ homeostasis, also in the context of pancreatic β-cells, thus connect-
ing calcium to diabetes28,47–49. In support of a role for WFS1 in regulating Ca2+ efflux from ER to mitochondria, 
we provide the first direct evidence by Western blot that WFS1 protein localization is enriched in the MAM 
fractions, confirming previous indications from proteomic analysis50,51.
Our study, by tackling at clinical, biochemical, neuro-radiological and cellular levels the issue of mitochon-
drial dysfunction in WS, contributes substantially to clarify that mitochondrial dysfunction is not a primary event 
in the pathogenic mechanism, but may occur secondarily as a byproduct of calcium mishandling. The key inter-
action, in fact, is possibly localized at the MAMs, where we found that Wolframin is enriched. Further studies are 
warranted to mechanistically define the ER-mitochondrial calcium handling in the pathogenesis of WS. Calcium 
mishandling and ER-stress may have far reaching consequences in the context of neuronal cells19, representing a 
druggable target for therapeutic strategies in WS patients, as suggested by WFS1 knock-out cell models47,52.
Methods
Ethical approval and consent to participate. All the procedures on patients were conducted according 
to the Declaration of Helsinki and after having obtained the approval of the Independent Ethical Committee 
“Area Vasta Emilia Centro CE-AVEC” (CE 211/2018/SPER/AUSLBO). Informed written consent for study par-
ticipation have been obtained from patients and volunteers.
Patient cohort. We investigated a cohort of 13 WS adult cases (5 males) carrying recessive mutations in 
WFS1 gene. Clinical information included family history, onset of OA and DM. Other cardinal symptoms of WS, 
concomitant pathologies and therapies were also collected.
Genetic testing. Genetic testing was performed by direct sequencing of the WFS1 gene53, or by a next gen-
eration sequencing based (Illumina, TruSeq Custom Amplicon) diagnostic panel dedicated to hereditary optic 
neuropathies, including WFS1.
Neuro-ophthalmological assessment. Neuro-ophthalmological examination included visual acuity, 
color vision (Ishihara test), pupil light reflex, slit lamp examination and fundus picture. Assessment of the anterior 
visual pathways was performed through VF (Humphrey Field Analyzer, protocol Sita Standard 30-2, Zeiss, San 
Leandro, CA, USA) and OCT. OCT protocol included the evaluation of RNFL thickness (Stratus 3.0, Carl Zeiss 
morphology (filamentous, intermediate and fragmented mitochondria) by blind test. 30–50 cells for each cell 
line and condition were scored. Data are expressed as mean ± s.d. of three independent experiments for each 
cell line. (H) Mitochondrial network morphology evaluated by confocal microscopy, in glucose-medium and 
after 48 hours of incubation in the galactose-medium. Mitochondria are stained with MitoTracker Red (red 
fluorescence) and nuclei are stained with Hoecsht (blue fluorescence), representative images are reported in 
the figure. White bar, 25 µm. All data are expressed as mean of two control fibroblasts (CTRLS) and two WFS1 
mutant fibroblasts (WS).
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Figure 4. Intracellular Ca2+assessment and MAM localization of WFS1. (A,B) ER Ca2+ release induced in 
fibroblasts from controls and WS patients by stimulation with 1 µM Bradykinin. Cell were transfected with the 
ER- Ca2+ sensor D1ER. Changes in ER-Ca2+ release were monitored by evoking Ca2+ release via iP3 receptors 
on the ER. Representative traces (A) and graph depicting the FRET ratio (B) are shown. Data are expressed 
as mean ± s.d. of three independent experiments for each cell line. *p < 0.05 unpaired t-test. (C,D) Aequorin-
based measurements of mitochondrial Ca2+ uptake induced in fibroblasts from controls and WS patients by 
stimulation with 1 µM Bradykinin. Data are expressed as mean ± s.d. of three independent experiments for each 
cell line. *p < 0.05 unpaired t-test. (E,F) Aequorin-based measurements of cytosolic Ca2+ induced in fibroblasts 
from controls and WS patients by stimulation with 1 µM Bradykinin. Data are expressed as mean ± s.d. of three 
independent experiments for each cell line. *p < 0.05 unpaired t-test. (G) Resting mitochondrial Ca2+ levels in 
control and WS fibroblasts evaluated by using ratiometric imaging of the mitochondrial targeted GCaMP. Data 
are expressed as mean ± s.d. of three independent experiments for each cell line. (H) Western blot of subcellular 
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Ophthalmic Systems Inc., Humphrey Division, Dublin, CA) according to the RNFL thickness 3.4 acquisition 
protocol, as previously described54 in 12/13 patients. We also performed and segmentation analysis of the retina55, 
including the GCL thickness (Heidelberg Spectralis HRA2, version 6.3.2.0, Heidelberg Engineering, Heidelberg, 
Germany) in a subgroup of 6/13 WS cases.
OCT data were compared to a control age and sex-matched group (n = 70 for RNFL thickness and n = 6 for 
GCL analyses) and to a pathological control groups composed by OPA1-mutated DOA patients (n = 16 for RNFL 
thickness and n = 6 for GCL analyses). DOA and WS patients were comparable in terms of visual acuity (DOA 
0.24 ± 0.17, WS 0.22 ± 0.21).
At the beginning of the examination, lenses were adjusted for the patient refractive error. Polarization was 
optimized to maximize the reflective signal, and the best centration of the scan with respect to the optic disk was 
used. For the statistical analysis, 1 eye was randomly chosen, after verification that there was no statistical differ-
ence between the 2 eyes, as previously reported54.
Lactic acid after standardized effort test. We evaluated lactic acid at baseline and after standardized 
exercise, as previously reported56 in 12/13 WS patients. Lactic acid plasma levels of WS patients were compared 
to the normative data provided by our local laboratory.
Muscle biopsy. Three WS patients underwent muscle biopsy. Standard stains and histoenzymatic activities 
were carried out on liquid nitrogen cooled isopentane frozen specimens, as previously described57.
Brain MRi/1H-MRS and skeletal muscle 31P-MRS acquisitions. All MRI studies were performed in 
a 1.5 T scanner.
Ten WS patients (3 M, mean age 29 ± 12 years) performed brain MR using a quadrature birdcage head 
coil. The acquisition protocol included the following sequences: volumetric FSPGR-T1 (voxel = 1 mm3), axial 
FLAIR-T2, coronal FSE T2, diffusion weighted imaging, DWI, (25 gradient directions, b-value = 900 s mm−2, 
voxel=1.25 × 1.25 × 4 mm). Moreover, water-suppressed proton MR spectra were acquired by the point-resolved 
spectroscopy single-voxel localization sequence (PROBE), as previously reported58, in the lateral ventricles 
in ten WS patients (TR/TE = 1500/288 ms, volume = 3.7–8.2 ml), in the left cerebellar hemisphere in 9 (TR/
TE = 4000/35 ms, volume = 6 ml), in the left POWM in 7 (TR/TE = 4000/35 ms, volume = 8 ml) and in the ven-
tral pons in 5 (TR/TE = 1500/40 ms, volume = 1.2–1.5 ml).
Volumetric FSPGR-T1, DWI, and 1H-MRS spectra were also acquired in sex- and age-matched healthy sub-
jects (see Additional files 1, 2 and 3, and corresponding legends, for demographic details).
Eight WS patients underwent muscle 31P-MRS examination using an 8-cm diameter surface coil placed under 
the right calf, as previously reported59; six of them also performed an aerobic exercise. Not all the patients com-
pleted the whole protocol. A group of sex- and age-matched healthy subjects was also studied.
Brain MRi and 1H-MRS analysis. Brain MRI scans were reviewed by two experienced neuroradiolo-
gists (RL, LLG) blinded to the clinical data. Results were reported as consensus between the two examiners. 
Voxel-based morphometry (VBM) analyses were performed with SPM-12.0 supplemented by SUIT, Spatially 
Unbiased Infratentorial Toolbox60,61, to assess voxel-wise cortical gray matter volumes. FreeSurfer was used 
to determine Total Intracranial Volume (TIV) and extract subcortical region volumes. Diffusion-weighted 
data underwent standard pre-processing and tensor fitting with FSL (FMRIB Software Library), and TBSS 
(Tract-Based Spatial Statistics) analysis was also performed. 1H-MR spectra were analyzed with LCModel version 
6.3.
Muscle 31P-MRS analysis. The fitting software AMARES/MRUI (http://www.jmrui.eu/) was used to esti-
mate peak integrals for PCr, inorganic phosphate (Pi), and the β phosphate of ATP.
Concentrations of metabolites, cytosolic pH, rate of PCr post-exercise recovery (expressed as time constant, 
TC) and maximum rate of mitochondrial ATP synthesis (Vmax) were calculated as previously reported59.
Fibroblast cell studies. Fibroblasts from two WS patients carrying respectively the compound heterozygous 
c.1369 A > G (p.R457G)/c.2104 G > A (p.G702S) (n.6 in Table 1) and homozygous c.2206 G > A (p.G736S) (n.9 in 
Table 1) WFS1 mutations and two controls were analyzed for WFS1 protein expression, mitochondrial function 
and Ca2+ efflux. Fibroblasts were established from skin biopsies, after having obtained informed and written 
consent from all patients and controls for the study and for all procedures. The A549 lung cancer cell line was also 
used for MAMs isolation.
Cells were grown in high glucose DMEM medium (Gibco) supplemented with 10% fetal bovine serum (FBS) 
(Gibco), 2mM L-glutamine, 100 U/mL penicillin and 100U/ml streptomycin and maintained at 37 °C in an incu-
bator under a humidified 5% CO2 atmosphere.
Total protein lysates were obtained as previously described62. Protein samples were separated on precast 
NuPAGE 4–12% Bis-Tris Glicyne gels (Life Technologies) and then transferred on nitrocellulose membranes, 
using the XcellSure Lock (Life Technologies) apparatus. After blocking with 5% milk, membranes were blotted 
with primary antibodies anti-WFS1 (Cell Signaling) 1:1000, anti-GAPDH (Sigma Aldrich) 1:10000, anti-IP3R-3 
fractions isolated from A549 cells, where IP3R3 was used as an ER marker, Sigma 1-R as a MAM marker, VDAC 
as a mitochondria marker and β-Tubulin as cytosolic marker. TOTAL, total lysate; Mp, pure mitochondria; ER, 
endoplasmic reticulum; MAMs, mitochondria-associated membranes; CYTO, cytosol. Image is generated by 
grouping different parts of the same blot (original images in Supplementary information file).
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(BD Biosciences) 1:1000, anti-TUBB (Cell Signaling) 1:1000, anti-VDAC1 (abcam) 1:1000, anti-sigmaR1 (Sigma, 
HPA018002) 1:1000.
Fluorescent secondary antibodies anti-rabbit or anti-mouse (Licor, 1:5000) were used for immunodetection 
using the LI-COR Odyssey Fc Dual Mode imager.
Mitochondrial respiration was evaluated measuring OCR and ECAR in live cells by the Seahorse XFe24 Flux 
Analyzer (Agilent), in basal conditions and after the addition of oligomycin (1uM), FCCP (2uM), rotenone (1uM) 
and Antimycin A (1uM). OCR and ECAR values were normalized on cell density using the colorimetric sulfo-
rodhamine B (SRB) assay. Basal, ATP-linked, and maximal respiration were calculated as previously described63.
Mitochondrial membrane potential was evaluated using JC-1 fluorescent probe (Thermo Fischer). Briefly, 
50.000 cells were seeded on a 96-well plate (View plate, Perkin Elmer) and the day after treated with JC-1 at 5ug/
ml concentration at 37 °C. After 20 minutes, cells were washed with PBS and incubated with high-glucose DMEM 
without phenol red and the 529 nm and 590 nm fluorescences were acquired in a plate reader (Enspire, Perkin 
Elmer).
Cellular ATP and mitochondrial network morphology were assessed both in standard conditions 
(glucose-medium) and after 48 hours of incubation in glucose-free medium supplemented with 5 mM galactose 
(galactose-medium), to force the mitochondrial respiratory chain. Total ATP was quantified using the ATPlite 
1step Luminescence Assay System (Perkin Elmer), following manufacturers’ instructions.
Mitochondrial network morphology was evaluated in living cells, stained with Mito Tracker Red (Thermo 
Fischer) at 10 nM and Hoechst (Thermo Fischer) at 1ug/ml for 20 minutes at 37 °C. Z-stack (0.8 µm) images 
were captured with an A1 confocal microscope (Nikon Instruments) using a 60x/1.4-NA oil objective and max-
imum intensity projections were generated using the NIS-elements software (Nikon Instruments). At least 30 
cells for each cell line and condition were evaluated in three independent experiments by blind test and classi-
fied into three categories based on the mitochondrial morphology (filamentous, intermediate and fragmented 
mitochondria)57.
ER Ca2+ release was performed by using the cameleon (calcium sensor) targeted to ER compartment, D1ER. 
After 36 h from the transfection, fibroblasts were imaged on a Zeiss Axiovert 200 M microscope with equipped 
with a C-apochromat 40× oil objective (numerical aperture 1.2). Images were captured by using a cooled CCD 
camera (Photometrics) controlled by MetaFluor 7.0 software (Universal Imaging). The Fluorescence Resonance 
Energy Transfer (FRET) signal (yellow fluorescent protein (YFP)/CFP) was normalized and changes in ER Ca2+ 
releases (evoked by the agonist BK) were expressed as the ratio of the emissions at 535 and 470 nm.
To evaluate mitochondrial and cytosolic Ca2+ uptake, cells were grown on 13-mm round glass coverslips 
at 60–70% confluence and transduced with aequorin encoded by adenoviral construct mitochondria-targeted 
mutated aequorin (mtAEQ) and an adenoviral construct cytosolic targeted aequorin (cytAEQ), respectively. The 
coverslips with the cells were then incubated with 5 μM coelenterazine for 2 hours in 0.1% FBS medium, and 
then transferred to the perfusion chamber. All aequorin measurements were performed in Krebs-Ringer buffer 
(135 mM NaCl, 5 mM KCl, 1 mM MgSO4, 0.4 mM KH2PO4, 5.5 mM glucose, 20 mM HEPES, pH 7.4) supple-
mented with 1 mM CaCl2. Agonists were added to the same medium, as specified in the text. To discharge the 
remaining aequorin pool, cells were lysed in a hypotonic Ca2+−rich solution (10 mM CaCl2 in H2O) with 100 μM 
digitonin. The light signal was calibrated into [Ca2+] values by an algorithm, as previously described64.
To evaluate resting mitochondrial Ca2+ levels, CTRL and WS mutant fibroblasts were allowed to grow on 
24 mm coverslips and transfected with mtGCaMP6m-encoding plasmid. After 36 hours, coverslips were placed 
in 1 ml of modified KRB (5.5 mM glucose, 1 mM CaCl2) and imaged at the Olympus Cell^R multiple wavelength 
high-resolution fluorescence microscopy system equipped with a 20x/1.3 N.A. Oil. Basal fluorescence of the mtG-
cAMP ratio (494/406) was registered for 1 min for each condition.
Cell fractionation was performed in A549 lung cancer cell line, as previously described65. Briefly, a cells pellet 
was suspended in homogenization buffer (225 mM mannitol, 75 mM sucrose, 30 mM Tris-HCl pH 7.4, 0.1 mM 
ethylene glycol-bis(β-aminoethylether)-N,N,N,N-tetraacetic acid (EGTA), and PMSF (phenylmethylsulfonyl flu-
oride) and gently disrupted by Dounce homogenization. The homogenate was centrifuged to remove nuclei and 
unbroken cells, and the resultant supernatant was centrifuged to pellet crude mitochondria. Centrifugation of the 
supernatant at 100.000 g for 90 min (70-Ti rotor; Beckman) resulted in the isolation of ER (pellet) and cytosolic 
fraction (supernatant). To collect pure mitochondria, crude mitochondria were resuspend in buffer density gra-
dient buffer (225 mM mannitol, 25 mM HEPES, pH 7.4, 1 mM EGTA, 0.1% BSA, 30% Percoll (v/v). After centrif-
ugation, the mitochondrial fraction was isolated two-thirds of the way down the tube, and the MAMs complex 
was found directly above the mitochondrial fraction.
Statistical analysis. For ophthalmological and cell studies all numerical data are expressed as mean ± SD. 
Welch’s unequal variances t-test was used for statistical analysis, unless otherwise indicated. Differences were 
considered statistically significant for p < 0.05. Normal distribution was assessed with Kolgomorov-Smirnov test 
and Bonferroni correction applied for multiple comparisons.
For MR data, group comparisons were performed with univariate analyses (SPSS®) controlling for TIV in 
volumetric data. Correlations were performed with Spearman correlation test (SPSS®). Voxelwise comparisons 
were done with non-parametric analysis and statistical significance was set at p < 0.05 (corrected for multiple 
comparisons).
Consent for publication. All the authors have approved the manuscript.
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